Ubiquitin-mediated degradation of cellular proteins: Why destruction is essential for construction, and how it got from the test tube to the patient's bed

Israel Medical Association Journal

Volumn 3, Issue 5, 2001, Pages 319-327

  Ciechanover, Aaron ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cancer; Degradation; Neurodegeneration; Proteins; Ubiquitin

Indexed keywords

CELLS; DEGRADATION; INFORMATION ANALYSIS; NUCLEIC ACIDS;

PATHOGENESIS;

PROTEINS;

CELL PROTEIN; NUCLEIC ACID; PROTEASOME; PROTEINASE; SCAVENGER; UBIQUITIN;

CELL DEATH; CELL ORGANELLE; CONJUGATION; CYSTIC FIBROSIS; GASTROINTESTINAL TRACT; GENETIC CODE; HAPPY PUPPET SYNDROME; HOSPITAL BED; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIDDLE SYNDROME; LYSOSOME; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MUSCLE ATROPHY; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN SYNTHESIS REGULATION; PROTEIN TRANSPORT; REVIEW;

ANGELMAN SYNDROME; DISEASE; HUMANS; IMMUNITY; INFLAMMATION; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEINS; UBIQUITINS;

EID: 0035716524     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. The ubiquitin system
2. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
3. Signal transduction through the β-catenin and specification of cell fate during embryogenesis
4. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin
5. Wnt signaling and cancer
6. Cdk inhibitors: Positive and negative regulators of G1-phase progression
7. Regulation of the CDK inhibitor p27 and its deregulation in cancer
8. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
9. Regulation of the epithelial sodium channel (ENaC) by accessory proteins
10. UBE3A/E6-AP mutations cause Angelman syndrome
11. Angelman syndrome: A review of clinical and genetic aspects
12. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons
13. Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders
14. Degradation of α-synuclein by proteasome
15. The ubiquitin pathway in Parkinson's disease
16. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
17. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
18. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1
19. Frameshift mutants of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients
20. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease
21. Endoproteolytic cleavage and proteasomal degradation of Presenilin 2 in transfected cells
22. Expression of Alzheimer's disease-associated Presenilin-1 is controlled by proteolytic degradation and complex formation
23. Polyglutamine pathogenesis
24. Triplet repeat expansion in neuromuscular disease
25. Ubiquitin, cellular inclusions and their role in neurodegeneration
26. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme
27. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
28. Biosynthesis and degradation of CFTR
29. Degradation of cell proteins and the generation of MHC class I-presented peptides
30. Phosphorylation meets ubiquitination: The control of NF-κB activity
31. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
32. Inhibition of ubiquitin-proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr Virus Nuclear Antigen (EBNA)-1
33. The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate
34. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway
35. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states
36. Inhibition of NF-κB cellular function via specific targeting of the Iκ6Bα-ubiquitin ligase
37. Induction of apoptosis in human papillomavirus positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein
38. Kip1, a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells
39. Kip1 is the key mediator of phenylacetate-induced cell cycle arrest in human prostate cancer cells